Analysts expect Syros Pharmaceuticals Inc (NASDAQ:SYRS) to announce $420,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Syros Pharmaceuticals’ earnings, with the highest sales estimate coming in at $500,000.00 and the lowest estimate coming in at $400,000.00. Syros Pharmaceuticals reported sales of $370,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 13.5%. The firm is expected to report its next quarterly earnings report on Thursday, May 9th.
According to Zacks, analysts expect that Syros Pharmaceuticals will report full-year sales of $1.70 million for the current financial year, with estimates ranging from $1.60 million to $2.00 million. For the next financial year, analysts expect that the firm will report sales of $1.87 million, with estimates ranging from $1.60 million to $2.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.05). The business had revenue of $0.89 million during the quarter, compared to analyst estimates of $0.40 million. Syros Pharmaceuticals had a negative return on equity of 64.43% and a negative net margin of 3,038.00%.
Shares of Syros Pharmaceuticals stock traded up $0.15 during trading on Friday, reaching $7.20. The company’s stock had a trading volume of 134,605 shares, compared to its average volume of 293,357. The stock has a market capitalization of $236.44 million, a price-to-earnings ratio of -3.77 and a beta of 1.30. Syros Pharmaceuticals has a 1-year low of $5.17 and a 1-year high of $13.81.
In related news, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of the firm’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $7.83, for a total value of $1,311,548.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Srinivas Akkaraju bought 533,332 shares of Syros Pharmaceuticals stock in a transaction that occurred on Tuesday, April 9th. The stock was purchased at an average price of $7.50 per share, with a total value of $3,999,990.00. The disclosure for this purchase can be found here. 27.80% of the stock is owned by company insiders.
A number of hedge funds have recently modified their holdings of SYRS. Bank of America Corp DE raised its stake in Syros Pharmaceuticals by 205.9% in the 4th quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after acquiring an additional 11,711 shares during the last quarter. Rhumbline Advisers raised its stake in Syros Pharmaceuticals by 51.4% in the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock worth $181,000 after acquiring an additional 10,995 shares during the last quarter. MetLife Investment Advisors LLC raised its stake in Syros Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock worth $242,000 after acquiring an additional 7,230 shares during the last quarter. Alps Advisors Inc. raised its stake in Syros Pharmaceuticals by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 77,768 shares of the company’s stock worth $433,000 after acquiring an additional 18,215 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Syros Pharmaceuticals by 8.9% in the 4th quarter. Bank of New York Mellon Corp now owns 84,537 shares of the company’s stock worth $470,000 after acquiring an additional 6,883 shares during the last quarter. Institutional investors own 67.87% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.
Read More: What are gap-down stocks?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.